Loading...
•
Mar 31
IDEX Q1 2025 Earnings Report
IDEX reported mixed first quarter results with slight revenue growth but lower profitability due to restructuring and acquisition-related costs.
Key Takeaways
IDEX delivered Q1 2025 revenue growth driven by acquisitions, but net income and EPS declined due to restructuring expenses and higher costs.
Revenue reached $814.3M, up 2% from Q1 2024, driven by the Mott acquisition.
Adjusted EPS declined to $1.75 from $1.88, reflecting increased costs and tax impacts.
Net income dropped to $95.5M, impacted by restructuring charges and higher interest expenses.
Strong order growth and backlog expansion, particularly in HST and FSDP segments.
IDEX
IDEX
IDEX Revenue by Segment
Revenue by Segment
Health & Science Technologies Revenue
CapyFin.comFluid & Metering Technologies Revenue
CapyFin.comFire & Safety/Diversified Products Revenue
CapyFin.com Forward Guidance
IDEX expects stable 2025 performance supported by cost containment measures and solid order trends, with potential risks from tariffs and slower demand.
Positive Outlook
- Full-year adjusted EPS guidance maintained at $8.10 - $8.45.
- Organic sales growth expected at 1% to 3% for FY25.
- Second quarter adjusted EPS forecasted at $1.95 - $2.05.
- Cost savings of $20M planned to counter tariff-related pressures.
- Order rates remain strong through April despite macro uncertainties.
Challenges Ahead
- Anticipated customer caution and slower decision-making.
- Higher interest and depreciation expenses impacting profitability.
- Continued softness in semiconductor, agriculture, and energy markets.
- Negative free cash flow trend due to inventory and interest payments.
- Dilutive impact from Mott acquisition on margins.
Revenue & Expenses
Visualization of income flow from segment revenue to net income